Loading...
XTAI
1762
Market cap85mUSD
Oct 08, Last price  
35.35TWD
1D
4.28%
1Q
-7.34%
Jan 2017
30.68%
IPO
-43.98%
Name

Chunghwa Chemical Synthesis & Biotech Co Ltd

Chart & performance

D1W1MN
XTAI:1762 chart
P/E
—
P/S
3.38
EPS
—
Div yield, %
0.54%
Shrs. gr., 5y
-6.64%
Rev. gr., 5y
-12.21%
Revenues
805m
-40.26%
1,126,848,0001,197,243,0001,200,576,0001,329,584,0001,043,480,000946,704,0001,162,211,0001,198,670,0001,168,248,0001,019,452,0001,156,642,0001,543,589,0001,934,702,0002,117,144,0002,086,441,0001,347,375,000804,878,000
Net income
-244m
L
245,105,000187,004,000170,994,000175,564,00096,825,00014,592,000308,356,00060,283,00085,766,000234,251,000117,003,000531,873,000400,778,000465,865,000264,909,00053,032,000-243,847,000
CFO
143m
-69.51%
462,069,000275,614,000144,843,000268,465,000145,240,00023,081,00079,705,000261,313,000159,339,000234,664,000268,128,000138,235,000219,179,000733,779,000-77,503,000467,654,000142,611,000
Dividend
Jul 24, 20250.19159 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Based in New Taipei City, Taiwan, Chunghwa Chemical Synthesis & Biotech Co., Ltd., established in 1964 and previously known as China Chemical Synthesis Industry Co., Ltd., specializes in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's market reach includes Taiwan and the United States. Their API portfolio encompasses products designed for immunosuppression, oncology, and cardiovascular conditions, in addition to various peptide compounds. Moreover, they manufacture a wide array of bulk pharmaceutical substances for numerous therapeutic applications, including anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular medications, skeletal muscle relaxants, hypolipidemics, antineoplastics, antihyperlipidemics, and immunosuppressants. Complementing its product offerings, Chunghwa Chemical Synthesis & Biotech delivers bespoke research and development as well as contract manufacturing services to both emerging drug developers and established generic pharmaceutical firms.

Key people

I-Chen Wang Hsien
Chairman of the Board · since 2020
Hou-Kai Wang
Vice Chairman of the Board · since 2024
Kuan-Chieh Wang
Finance Manager, Head of Finance & Accounting · since 2020
Wen-Yu Hsiao
General Manager · since 2025
Qing-Peng Wei
General Manager · since 2022
Ying-Chi Chen
Deputy General Manager-Business Division · since 2019
Hou-Jie Wang
Director · since 2020
Shixuan Wu
Director · since 2025
Chih-Hsien Chang
Independent Director · since 2016
Arthur Kuan
Independent Director · since 2022
Mingjie Li
Independent Director · since 2025
Independent Director · since 2010
IPO date
Dec 10, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT